Drugs / 11β-MNTDC
11β-MNTDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02754687 | Jul 2016 → Jan 2017 | — | Premier Research | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11β-MNTDC | “11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity.” PMID 30252057 ↗ Mar 2019 |
| Known as | 11β-Methyl Nortestosterone Dodecylcarbonate | “This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men followed on an inpatient basis to evaluate the safety and tolerability,...” NCT02754687 ↗ |
| Known as | 11β-Methyl-19-nortestosterone-17β-dodecylcarbonate | “11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity.” PMID 30252057 ↗ Mar 2019 |
| Known as | 11β-MNT dodecylcarbonate | “In two clinical trials of DMA undecanoate (DMAU) and 11β-MNT dodecylcarbonate (11β-MNTDC), oral prodrugs of DMA and 11β-MNT, healthy men received drug, or placebo for 28 days.” PMID 33908182 ↗ May 2021 |
| Route | Oral | “Participants and Intervention: Twelve healthy male volunteers were randomized (five active, one placebo) to escalating single oral doses (100, 200, 400, and 800 mg) of...” PMID 30252057 ↗ Mar 2019 |